Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy

Impact · against what's priced in

The stock remains a binary bet on the STARS-2 trial, as the market has already accounted for the inevitable revenue cliff facing Linzess by 2029. The current valuation reflects the pressure from Medicare price cuts and debt obligations, leaving limited upside unless apraglutide delivers successful trial results.

IRWD+0.10

No priced-in read yet

In context

While the $456 million peak sales potential for apraglutide provides a growth path, the timeline is constrained by expected generic competition for Linzess by 2029 and immediate margin pressure from Medicare price cuts.

Read from the article alone

• pharmaceuticals
• biotech
• IRWD
• clinical trials
• drug pipeline
• fda approval
• generic competition
• medicare

Search tags